Celgene signs Jounce as its new biotech star in $2.6B ‘immuno-oncology 2.0’ pact
Over the past year Celgene has committed $1.25 billion in cash – plus billions more in milestones – to a pair of major immuno-oncology deals with Juno and Agios. Today, Celgene has chosen its new star partner for cancer R&D, stepping up with a richly front-ended $2.56 billion deal to collaborate with upstart Jounce Therapeutics’ on its lead I/O program, plus a package of treatments in discovery.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
